Eisai Inc., of Woodcliff Lake, N.J., the U.S. pharmaceutical operation of Tokyo-based Eisai Co. Ltd., has pledged as much as $200 million in research funding to start-up H3 Biomedicine, of Cambridge, Mass., which hopes to develop oncology treatments genetically tailored to patients' cancers.